Clinical Trials Browser

Phase 3 × INDUSTRY × Gastrointestinal × Clear all

NCT03653507 2026-04-17

GLOW

Phase 3 Active not recruiting

507 enrolled 65 charts 3 FDA

Gastrointestinal

Adenocarcinoma, Neoplasms, Stomach Neoplasms

NCT04543617 2026-04-17

SKYSCRAPER-07

Phase 3 Active not recruiting

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT05152147 2026-04-17

HERIZON-GEA-01

Phase 3 Active not recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms, Stomach Neoplasms

NCT05171075 2026-04-17

MAGNOLIA

Phase 3 Terminated

Classical hematologyGastrointestinal

Gastrointestinal Neoplasms, Pulmonary Embolism, Venous Thrombosis, Venous Thromboembolism

NCT05239741 2026-04-17

MK-3475-C66

Phase 3 Recruiting

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT05884255 2026-04-17

An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.

Phase 3 Recruiting

EndocrineGastrointestinalNET

Advanced Gastroenteropancreatic Neuroendocrine Tumor

NCT06304974 2026-04-17

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus01)

Phase 3 Active not recruiting

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT06467357 2026-04-16

DESTINY-BTC01

Phase 3 Recruiting

Gastrointestinal

Biliary Tract Neoplasms

NCT06784752 2026-04-16

NETTER-3

Phase 3 Recruiting

EndocrineGastrointestinalLymphoidNET

Gastro-enteropancreatic neuroendocrine tumor, Lymphoma, Follicular

NCT07284849 2026-04-16

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Phase 3 Recruiting

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT07409272 2026-04-16

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

Phase 3 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT03778957 2026-04-15

EMERALD-1

Phase 3 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT04924062 2026-04-15

KEYNOTE-966

Phase 3 Completed

158 enrolled 19 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT06622057 2026-04-14

D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer

Phase 3 Not yet recruiting

Gastrointestinal

Biliary Tract Neoplasms, Cholangiocarcinoma

NCT03957590 2026-04-13

A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma

Phase 3 Completed

370 enrolled 17 charts

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT06662786 2026-04-13

OrigAMI-2

Phase 3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT06750094 2026-04-13

OrigAMI-3

Phase 3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT06997497 2026-04-13

KANDLELIT-012

Phase 3 Recruiting

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT07431281 2026-04-13

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

Phase 3 Recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Adenocarcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT07522073 2026-04-13

DAWN-303

Phase 3 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT07522151 2026-04-13

Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer

Phase 3 Not yet recruiting

Gastrointestinal

Locally Advanced Gastric or Gastroesophageal Junction Cancer

NCT07525206 2026-04-13

A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer

Phase 3 Not yet recruiting

Gastrointestinal

Colorectal Neoplasms

NCT04540211 2026-04-09

SKYSCRAPER-08

Phase 3 Completed

461 enrolled 24 charts

Gastrointestinal

Esophageal Neoplasms

NCT06764875 2026-04-09

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

Phase 3 Recruiting

Gastrointestinal

HER2-positive Gastric Cancer

NCT07265674 2026-04-09

Beacon-BTC

Phase 3 Recruiting

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT07222800 2026-04-08

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

Phase 3 Recruiting

Gastrointestinal

Colonic Diseases, Colonic Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasm Metastasis, Neoplasms by Site, Rectal Diseases, Colorectal Neoplasms

NCT07518147 2026-04-08

A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment

Phase 3 Not yet recruiting

Gastrointestinal

Stomach Neoplasms

NCT05253651 2026-04-07

MOUNTAINEER-03

Phase 3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT05301842 2026-04-07

EMERALD-3

Phase 3 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT04039607 2026-04-06

CheckMate 9DW

Phase 3 Active not recruiting

732 enrolled 3 FDA

Gastrointestinal

Carcinoma, Hepatocellular

NCT07228832 2026-04-06

HARMONi-GI3

Phase 3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT07252232 2026-04-06

RASolute 304

Phase 3 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT07491445 2026-04-06

RASolute 303

Phase 3 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT07218926 2026-04-03

A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

Phase 3 Recruiting

GastrointestinalSarcoma

Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors

NCT05568095 2026-04-02

STAR-221

Phase 3 Active not recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT06252649 2026-04-02

CodeBreaK 301

Phase 3 Recruiting

Gastrointestinal

Neoplasms, Colorectal Neoplasms

NCT06608927 2026-04-01

PRISM-1

Phase 3 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT05477576 2026-03-30

ACTION-1

Phase 3 Recruiting

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT04689594 2026-03-27

A Study to Evaluate the Esophageal Stenosis Inhibition Effects of CLS2702C/CLS2702D After Endoscopic Submucosal Dissection (ESD) in Patients With Superficial Esophageal Cancer in the Steroid Administration Risk Group

Phase 3 Terminated

Gastrointestinal

Superficial Esophageal Cancer

NCT05771480 2026-03-25

TOURMALINE

Phase 3 Active not recruiting

Gastrointestinal

Biliary Tract Neoplasms

NCT04003636 2026-03-24

KEYNOTE-966

Phase 3 Completed

1,069 enrolled 19 charts 2 FDA

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT06282575 2026-03-24

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

Phase 3 Recruiting

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT03298451 2026-03-20

HIMALAYA

Phase 3 Active not recruiting

1,324 enrolled 31 charts 2 FDA

Gastrointestinal

Carcinoma, Hepatocellular

NCT03875235 2026-03-19

TOPAZ-1

Phase 3 Active not recruiting

810 enrolled 24 charts 2 FDA

Gastrointestinal

Biliary Tract Neoplasms

NCT04102098 2026-03-19

IMbrave050

Phase 3 Active not recruiting

668 enrolled 11 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT04720716 2026-03-19

A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC

Phase 3 Completed

Gastrointestinal

Carcinoma, Hepatocellular

NCT06497985 2026-03-19

A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients

Phase 3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT07483684 2026-03-19

A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs

Phase 3 Not yet recruiting

Gastrointestinal

HER2 IHC3+ Advanced Colorectal Cancer

NCT06950385 2026-03-17

SERENTA

Phase 3 Recruiting

Gastrointestinal

Adenomatous Polyposis Coli, Polyps

NCT07221253 2026-03-17

AB02

Phase 3 Recruiting

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Recurrence